124 related articles for article (PubMed ID: 16928831)
1. Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer.
Yuan QA; Simmons HH; Robinson MK; Russeva M; Marasco WA; Adams GP
Mol Cancer Ther; 2006 Aug; 5(8):2096-105. PubMed ID: 16928831
[TBL] [Abstract][Full Text] [Related]
2. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning.
Yuan QA; Robinson MK; Simmons HH; Russeva M; Adams GP
Cancer Immunol Immunother; 2008 Mar; 57(3):367-78. PubMed ID: 17676323
[TBL] [Abstract][Full Text] [Related]
3. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
[TBL] [Abstract][Full Text] [Related]
4. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
5. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
6. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
9. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
10. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
[TBL] [Abstract][Full Text] [Related]
11. High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging.
Ortega C; Herbet A; Richard S; Kersual N; Costa N; Pèlegrin A; Ducancel F; Couraud JY; Navarro-Teulon I; Boquet D
J Immunol Methods; 2013 Jan; 387(1-2):11-20. PubMed ID: 22910001
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
[TBL] [Abstract][Full Text] [Related]
13. Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice.
El-Naggar SM; Malik MT; Martin A; Moore JP; Proctor M; Hamid T; Kakar SS
J Endocrinol; 2007 Jul; 194(1):179-91. PubMed ID: 17592032
[TBL] [Abstract][Full Text] [Related]
14. Isolating and engineering human antibodies using yeast surface display.
Chao G; Lau WL; Hackel BJ; Sazinsky SL; Lippow SM; Wittrup KD
Nat Protoc; 2006; 1(2):755-68. PubMed ID: 17406305
[TBL] [Abstract][Full Text] [Related]
15. Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines.
Rothe A; Klimka A; Tur MK; Pfitzner T; Huhn M; Sasse S; Mallmann P; Engert A; Barth S
Int J Mol Med; 2004 Oct; 14(4):729-35. PubMed ID: 15375609
[TBL] [Abstract][Full Text] [Related]
16. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
Mazumder S; Johnson JM; Swank V; Dvorina N; Martelli E; Ko J; Tuohy VK
Cancer Prev Res (Phila); 2017 Nov; 10(11):612-624. PubMed ID: 29093011
[TBL] [Abstract][Full Text] [Related]
17. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.
Figini M; Martin F; Ferri R; Luison E; Ripamonti E; Zacchetti A; Mortarino M; Di Cioccio V; Maurizi G; Allegretti M; Canevari S
Cancer Immunol Immunother; 2009 Apr; 58(4):531-46. PubMed ID: 18704410
[TBL] [Abstract][Full Text] [Related]
18. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
20. Generation of affinity matured scFv antibodies against mouse neural cell adhesion molecule L1 by phage display.
Dong L; Chen S; Bartsch U; Schachner M
Biochem Biophys Res Commun; 2003 Jan; 301(1):60-70. PubMed ID: 12535641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
